Drug intelligence / Profile preview

F. Hoffmann-La Roche SARM1 compound 7

Development stage: Preclinical
Lead developer: Roche

Overview

F. Hoffmann-La Roche SARM1 compound 7: sourced facts only. name: "We present herein the structure-guided discovery of two novel SARM1 inhibitors, 7 and 35." [PMID:40100796]; target: "We present herein the structure-guided discovery of two novel SARM1 inhibitors, 7 and 35." [PMID:40100796]; developer: "Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Grenzacherstrasse 124, 4070 Basel, Switzerland." [PMID:40100796]; stage: "When tested in vivo, compound 7 showed efficacy after oral dosing in a mouse model of peripheral nerve injury by decreasing plasma neurofilament light (NfL) levels at 50 mg/kg compared with vehicle-treated control mice, holding promise for the treatment of neurodegenerative and neurological disorders." [PMID:40100796]

Targets

SARM1

Beyond the preview

Go deeper on F. Hoffmann-La Roche SARM1 compound 7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on F. Hoffmann-La Roche SARM1 compound 7.